Notal Vision announced the company will provide AsclepiX Therapeutics with Home OCT monitoring services through its Notal Vision Diagnostic Clinic to support AsclepiX’s AXT107 phase 1 clinical trial program. The exploratory application of the investigational home monitoring platform will add new data points between the regularly scheduled study office visits.
Study subjects with diabetic macular edema (DME) and wet age-related macular degeneration (AMD), who participate in the CONGO and SHASTA study sponsored by AsclepiX Therapeutics, will perform sequential daily self-imaging of their eyes with the self-operated Notal Home OCT device in their homes. The Notal Vision Diagnostic Clinic will monitor patient compliance for daily self-imaging and provide remote support as needed. Data from the Home OCT device will be automatically transmitted via a built-in cellular modem to the secure Notal Health Cloud, where the AI-based Notal OCT Analyzer (NOATM) will identify and quantify intra- and subretinal fluid from each daily OCT volume scan. Home OCT images and temporal fluid volume trajectories will be shared with AsclepiX and can be made available to the investigators through the Notal Physician Portal.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
“Remote OCT monitoring of patients with exudative retinal diseases in a regulatory clinical trial allows AsclepiX Therapeutics to capture critical data points while potentially reducing the burden of frequent office visits” said Dr. Arshad M. Khanani, MD, MA, one of the study’s investigators and Director of Clinical Research at Sierra Eye Associates in Reno, NV. “The clinical value and potential benefit of such an approach is even more crucial now in light of the COVID-19 pandemic.”
“Home OCT monitoring opens new opportunities to enrich clinical trial datasets with inter-visit disease and treatment response knowledge,” said Kester Nahen, PhD, CEO of Notal Vision, Inc. “We are excited to partner with AsclepiX Therapeutics and contribute our remote diagnostic services to their early phase clinical trial program.”